The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Abstract
There is a dearth of information on the pharmacodynamics of “colistin,” despite its increasing use as a last line of defense for treatment of infections caused by multidrug-resistant gram-negative organisms. The antimicrobial activities of colistin and colistin methanesulfonate (CMS) were investigated by studying the time-kill kinetics of each against a type culture of Pseudomonas aeruginosa in cation-adjusted Mueller-Hinton broth. The appearance of colistin from CMS spiked at 8.0 and 32 mg/liter was measured by high-performance liquid chromatography, which generated colistin concentration-time profiles. These concentration-time profiles were subsequently mimicked in other incubations, independent of CMS, by incrementally spiking colistin. When the cultures were spiked with CMS at either concentration, there was a substantial delay in the onset of the killing effect which was not evident until the concentrations of colistin generated from the hydrolysis of CMS had reached approximately 0.5 to 1 mg/liter (i.e., ∼0.5 to 1 times the MIC for colistin). The time course of the killing effect was similar when colistin was added incrementally to achieve the same colistin concentration-time course observed from the hydrolysis of CMS. Given that the killing kinetics of CMS can be accounted for by the appearance of colistin, CMS is an inactive prodrug of colistin with activity against P. aeruginosa . This is the first study to demonstrate the formation of colistin in microbiological media containing CMS and to demonstrate that CMS is an inactive prodrug of colistin. These findings have important implications for susceptibility testing involving “colistin,” in particular, for MIC measurement and for microbiological assays and pharmacokinetic and pharmacodynamic studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Hancock, R. E. W., & Chapple, D. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1317 · Cited by 1,190
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Self-citationPolymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria
Evans, M. E., Feola, D. J., & Rapp, R. P. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18426 · Cited by 544
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Dathe, M., Wieprecht, T., Nikolenko, H., Handel, L., Maloy, W. L., MacDonald, D. L., Beyermann, M., & Bienert, M. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00055-0 · Cited by 409
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa
Rossolini, G. M., & Mantengoli, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01161.x · Cited by 395
Wu, M., & Hancock, R. E. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.29 · Cited by 356
Livermore, D. M. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1004.x · Cited by 314
Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Cationic Bactericidal Peptides
Hancock, R. E. W., Falla, T., & Brown, M. (1995) · Advances in Microbial Physiology · doi:10.1016/s0065-2911(08)60145-9 · Cited by 262
Linden, P. K., Kusne, S., Coley, K., Fontes, P., Kramer, D. J., & Paterson, D. (2003) · Clinical Infectious Diseases · doi:10.1086/379611 · Cited by 252
Mouton, J. W., & Vinks, A. A. T. M. M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00005 · Cited by 177
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
Berlana, D., Llop, J. M., Casamartina, E. F., Badia, M., & Jódar, R. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.1.39 · Cited by 155
Surveillance of antibiotic resistance in European ICUs
Hanberger, H., Diekema, D. J., Fluit, A. C., Jones, R. N., Struelens, M. J., Spencer, R. C., & Wolff, M. (2001) · Journal of Hospital Infection · doi:10.1053/jhin.2001.0987 · Cited by 138
Conway, S. P., Pond, M. N., Watson, A., Etherington, C., Robey, H. L., & Goldman, M. H. (1997) · Thorax · doi:10.1136/thx.52.11.987 · Cited by 136
SODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS
Barnett, M., Bushby, S. R. M., & Wilkinson, S. (1964) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1964.tb01610.x · Cited by 134
Li, J., Rayner, C. R., Nation, R. L., Deans, R., Boots, R. J., Widdecombe, N., Douglas, A., & Lipman, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4814-4815.2005 · Cited by 133
Self-citationIncreasing threat of Gram-negative bacteria
WATERER, G. W., & Wunderink, R. G. (2001) · Critical Care Medicine · doi:10.1097/00003246-200104001-00004 · Cited by 112
The threat from the pink corner
Livermore, D. M. (2003) · Annals of Medicine · doi:10.1080/07853890310001609 · Cited by 92
Streptomyces Differentiation in Liquid Cultures as a Trigger of Secondary Metabolism
Manteca, Á., & Yagüe, P. (2018) · Antibiotics · doi:10.3390/antibiotics7020041 · Cited by 91
Serological and molecular evidence of Rickettsia helvetica in Denmark
Nielsen, H., Fournier, P., Pedersen, I. S., Krarup, H. B., Ejlertsen, T., & Raoult, D. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410020776 · Cited by 72
A ten year review of Colomycin
Littlewood, J. M., Koch, C., Lambert, P. A., Høiby, N., Elborn, J. S., Conway, S. P., Dinwiddie, R., & Duncan-Skingle, F. (2000) · Respiratory Medicine · doi:10.1053/rmed.2000.0834 · Cited by 72
Cited by
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Self-citationHorcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Self-citation
Metadata
- Authors
- Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-06
- Volume
- 50
- Issue
- 6
- Pages
- 1953-1958
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2120266293
- Cited by
- 366
- References
- 24
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.